Sign in

CIK 0001501989 · Accelerated filer

CytomX Therapeutics, Inc.

Sign in to watch
Ticker
CTMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273521219
Phone
650.515.3185
Business address
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
  1. 10-K Report Annual Report
  2. 8-K Event Delisting notice
  3. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  4. 4/A Grant or award SVP, Chief Scientific Officer acquired 92,500 shares (grant or award)
  5. 4 Grant or award SVP, Chief Scientific Officer acquired 87,500 shares (grant or award)
  6. 4 Grant or award Chief Medical Officer acquired 113,500 shares (grant or award)
  7. 4 Grant or award Chief Financial Officer acquired 101,500 shares (grant or award)
  8. 4 Grant or award CEO acquired 375,000 shares (grant or award)
  9. 8-K Event Executive or director change
  10. 8-K Event Exit or restructuring costs
  11. SC 13G/A Stake Amended Statement of Ownership
  12. SC 13G/A Stake Amended Statement of Ownership
  13. SC 13G/A Stake Amended Statement of Ownership
  14. SC 13G/A Stake Amended Statement of Ownership
  15. 8-K Event Results of operations
  16. 10-Q Report Quarterly Report
  17. 4 Open-market sale Chief Business Officer sold 4,181 shares at $1.23 ($5,139)
  18. 4 Open-market sale SVP, Chief Scientific Officer sold 4,181 shares at $1.23 ($5,139)
  19. 4 Open-market sale General Counsel sold 4,181 shares at $1.23 ($5,139)
  20. 4 Open-market sale Chief Financial Officer sold 1,984 shares at $1.23 ($2,439)

Page 7 of 41 · 801 filings